Principal Investigator: Dr Chaoyang Ye
Blueprint Medicines Corporation, Massachusetts, USATags: 55385, biomarker, disease, GWAS, kinase
Kinases are a group of proteins involved in many diseases including cancers. Blueprint Medicines has generated large collection of highly effective drugs targeting them. With UKBB data, we hope to identify patients with abnormalities in those proteins that may benefit from our drugs. UKBB data will help us assess how many people are affected by the disease and what tests are needed for diagnosis. We expect the initial stage of the project to last for a year. Additional two years are needed to help us confirm findings with additional data. Continued refinement of those drugs will eventually benefit patient with their illnesses.